Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Original publication

DOI

10.1038/nrclinonc.2009.108

Type

Journal article

Journal

Nat Rev Clin Oncol

Publication Date

09/2009

Volume

6

Pages

499 - 500

Keywords

Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Antineoplastic Agents, Antineoplastic Agents, Phytogenic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Cetuximab, Cisplatin, Clinical Trials, Phase III as Topic, Dose-Response Relationship, Drug, Epidermal Growth Factor, ErbB Receptors, Follow-Up Studies, Humans, Lung Neoplasms, Proportional Hazards Models, Survival Analysis, Time Factors, Treatment Outcome, Vinblastine, Vinorelbine